Avanos Medical Inc is a global medical technology company focused on developing innovative solutions for pain management and recovery. The company specializes in the design and manufacture of a range of products, including advanced surgical devices, wound care solutions, and specialized treatments that enhance patient care and improve outcomes. With an emphasis on driving advancements in medical technology, Avanos aims to provide healthcare professionals with effective tools that promote healing, comfort, and overall well-being for patients across various healthcare settings. Read More
BALA CYNWYD, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners. Under the terms of the proposed transaction, shareholders of Avanos will receive $25.00 in cash for each share of Avanos that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
The medical technology landscape witnessed a seismic shift on Tuesday as Avanos Medical (NYSE: AVNS) announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.27 billion. The deal marks a significant turning point
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners for $25.00 per share in cash.
Avanos Medical (AVNS) beats Q2 2025 earnings with $175M revenue and $0.17 EPS, exceeding estimates. Shares surge 11.56% pre-market. New CFO appointed, outlook remains strong.
